We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+31.61%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.19B
AUM Growth
+$204M
Cap. Flow
+$48.2M
Cap. Flow %
4.04%
Top 10 Hldgs %
41.65%
Holding
184
New
58
Increased
50
Reduced
24
Closed
34

Top Buys

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22.4M
2
FOLD
Amicus Therapeutics
FOLD
+$14.4M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$13.8M
4
BLUE
bluebird bio
BLUE
+$11.6M
5
RLYP
RELYPSA INC COM
RLYP
+$11.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.3M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
3
ARWR icon
Arrowhead Research
ARWR
+$18.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.7M
5
HCA icon
HCA Healthcare
HCA
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.07%
2 Financials 0.1%
3 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANTH
101
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$795K 0.07%
62,895
+3,088
+5% +$44.9K
AKAO
102
DELISTED
Achaogen Inc
AKAO
$783K 0.07%
60,000
– –
DRRX
103
DELISTED
DURECT Corp
DRRX
$716K 0.06%
90,706
– –
PTLA
104
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$708K 0.06%
+25,000
New +$695K
BFYT
105
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$687K 0.06%
96,000
-35,025
-27% -$295K
SIEN
106
DELISTED
Sientra, Inc.
SIEN
$621K 0.05%
+3,700
New +$631K
CASC
107
DELISTED
Cascadian Therapeutics, Inc.
CASC
$618K 0.05%
54,167
– –
SPNC
108
DELISTED
Spectranetics Corp
SPNC
$565K 0.05%
16,335
-122,036
-88% -$3.8M
MTEM
109
DELISTED
Molecular Templates, Inc.
MTEM
$509K 0.04%
970
– –
GLMD icon
110
Galmed Pharmaceuticals
GLMD
$4.61M
$435K 0.04%
417
– –
RAD
111
DELISTED
Rite Aid Corporation
RAD
$318K 0.03%
+2,119
New +$235K
LHCG
112
DELISTED
LHC Group LLC
LHCG
$302K 0.03%
+9,688
New +$244K
RXII
113
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$302K 0.03%
+200,000
New +$302K
MRGE
114
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$293K 0.02%
82,427
+38,949
+90% +$115K
CLVS
115
DELISTED
Clovis Oncology, Inc.
CLVS
$288K 0.02%
5,138
-25,779
-83% -$1.35M
NSPH
116
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$277K 0.02%
+35,378
New +$330K
HNT
117
DELISTED
HEALTH NET INC
HNT
$269K 0.02%
+5,025
New +$247K
SKH
118
DELISTED
SKILLED HEALTHCARE GROUP, INC. CLASS A COM STK
SKH
$268K 0.02%
+31,293
New +$221K
SCLN
119
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$262K 0.02%
29,942
+13,907
+87% +$113K
INFI
120
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$259K 0.02%
+15,323
New +$223K
SCAI
121
DELISTED
Surgical Care Affiliates, Inc.
SCAI
$259K 0.02%
+7,702
New +$237K
CNC icon
122
Centene
CNC
$30.5B
$258K 0.02%
9,936
+4,592
+86% +$107K
GTS
123
DELISTED
Triple-S Management Corporation
GTS
$254K 0.02%
11,147
+4,966
+80% +$106K
PRPO icon
124
Precipio
PRPO
$38.6M
$253K 0.02%
14
-6
-30% -$140K
UHS icon
125
Universal Health Services
UHS
$10.2B
$248K 0.02%
2,233
+1,132
+103% +$119K
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Perceptive Advisors held 184 positions worth $1.19B, up 21% from $988M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Perceptive Advisors deployed $48.2M of net new capital in Q4 2014, opening 58 new positions and adding to 50 existing holdings. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was Celgene Corp, an estimated $24.3M trimmed.

  • Perceptive Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q4 2014, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q4 2014 reduction was Celgene Corp, cutting an estimated $24.3M.
  • Perceptive Advisors fully exited Arrowhead Research in Q4 2014, selling an estimated $18.4M.
  • Perceptive Advisors's ten largest holdings make up 42% of its $1.19B portfolio in Q4 2014.
  • Perceptive Advisors opened 58 new positions and closed 34 in Q4 2014.
  • Perceptive Advisors's portfolio value rose 21% quarter-over-quarter to $1.19B.

Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.